With new technologies that allow drugs to be tested directly in human biological systems, researchers are beginning to ...

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio ...

According to GSK, the programme of 'Grand Challenge' research projects will make use of AI and other cutting-edge ...

Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result ...

Towards that end, the European Society for Medical Oncology (ESMO) has developed a new guidance document that outlines the ...

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...

The launch of Sandoz's Tyruko biosimilar of Tysabri (natalizumab) comes two years after the product was approved by the FDA, ...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical ...

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in 1896 ...

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy US biotech Halda Therapeutics and ...

The announcement takes the total raised by Sofinnova Partners in the last year to €1.5 billion, and comes shortly after Anglo ...

As the Jefferies Healthcare conference gets underway this week in London, pharmaphorum had the chance to connect with the CEO ...